Company intelligence / Profile preview
Venthera
Palo Alto, CA, United Statesventhera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preliminary results from the ongoing Phase 1/2 trial of VT30/BBP‑681 show that Venthera’s topical PI3Kα inhibitor therapy for rare vascular anomalies has advanced to human studies. The trial aims to establish safety, tolerability, dosing regimen, and exploratory efficacy in patients with VMs, LMs, and VLMs driven by PIK3CA or TEK mutations. Results are still preliminary; full efficacy data have not yet been published.
- Therapeutic areas
- Rare DiseasesCardiovascular
- Modalities
- Small molecules (specifically topical PI3Kα inhibitors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
BridgeBio Pharma affiliation/support; no major external pharma partnerships disclosed
Beyond the preview
Go deeper on Venthera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Venthera.